Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | FABP4 | P15090 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383427 | 0.95 | ALDH1A1 (0.97) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL9869808 | 0.93 | ALDH1A1 (1.00) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL31522350 | 0.93 | ALDH1A1 (1.00) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL9567621 | 0.93 | ALDH1A1 (1.00) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL9869749 | 0.93 | ALDH1A1 (1.00) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL599970 | 0.93 | ALDH1A1 (1.00) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL9567728 | 0.93 | ALDH1A1 (1.00) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL4595308 | 0.93 | ALDH1A1 (1.00) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL2009291 | 0.90 | ALDH1A1 (0.72) | ALDH1A1TBXA2RLMNAKDM4EPKM | |
| SCHEMBL1200801 | 0.89 | ALDH1A1 (0.75) | ALDH1A1TBXA2RLMNAKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123253-B1 | WRINKLING-PREVENTING AND -ALLEVIATING AGENT | SHISEIDO CO LTD (JP) | 2017-06-28 | — | — | EP | claimed |
| CN-101677931-B | Wrinkling-preventing and -modifying agent | SHISEDO CO LTD | 2013-01-02 | — | — | CN | claimed |
| US-8173705-B2 | Agent for alleviating wrinkles | SHISEIDO COMPANY LTD. (JP) | 2012-05-08 | — | — | US | claimed |
| US-20100113450-A1 | Agent for Preventing and Alleviating Wrinkles | SHISEIDO COMPANY LTD. (JP) | 2010-05-06 | — | — | US | claimed |
| EP-2123253-A1 | WRINKLING-PREVENTING AND -MODIFYING AGENT | Shiseido Company, Ltd. (JP) | 2009-11-25 | — | — | EP | claimed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2123253-B1 | WRINKLING-PREVENTING AND -ALLEVIATING AGENT | SHISEIDO CO LTD (JP) | 2017-06-28 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| JP-5348922-B2 | — | — | 2013-11-20 | — | — | JP | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-7417022-B2 | Compounds and compositions for delivering active agents | MHR INSTITUTIONAL PARTNERS IIA LP (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-0288685-B1 | USE OF PYRROLIDONE DERIVATIVES AS ANTI-AMNESTIC AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1993-05-26 | — | — | EP | disclosed |
| US-4833156-A | Treating amnesia with a pyrrolidone derivative | KIRIN BEER KABUSHIKI KAISHA (JP) | 1989-05-23 | — | — | US | disclosed |
| EP-0288685-A2 | Use of pyrrolidone derivatives as anti-amnestic agents | KIRIN BEER KABUSHIKI KAISHA (JP) | 1988-11-02 | — | — | EP | disclosed |
| US-4761430-A | ANTILIPEMIC AGENTS | DROPIC, SOCIETE CIVILE DE GESTION DE DROITS DE PROPRIETE INDUSTRIELLE (FR) | 1988-08-02 | — | — | US | disclosed |
| US-4613618-A | VEGETABLE OILS, VASODILATORS | CHOAY S.A. (FR) | 1986-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | ARSA, CNKSR1, BCL9L | ALDH1A1 1548/4885TBXA2R 3543/4885LMNA 4440/4885 |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | ALDH1A1 3386/4885TBXA2R 196/4885LMNA 4030/4885 |
| US-20100113450-A1 | Agent for Preventing and Alleviating Wrinkles | GABRB1, GABRB2, GABBR1 | ALDH1A1 392/4885TBXA2R 154/4885LMNA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.